The company specializes in providing protein engineering to pharmaceutical and biotechnology companies for the discovery, identification and design of new peptide, polypeptide, protein and antibody compounds using their proprietary technology.
Primary goals of the company are the development and the establishment of innovative bioinstrumentation based on Femtosecond Laser Technology for biotechnology, cell biology and medicine, e.g. nanoprocessing with femtosecond near infrared laser pulses.
Keystone Nano has an exclusive license to Penn State patented technology that allows the creation of stable, non-toxic, 5 to 50 nm-composite particles that they call Molecular Dots (MDs). These Molecular Dots can encapsulate drugs and/or fluorescent molecules.
A cell culture/biotech company making strides in enhancing organ preservation and cell culturing at both room temperature and through cryopreservation. The LIFOR® technology is the nanoparticle component of the solution, which carries the oxygen or any type of drug or nutrient that the developers wish to place into the nanoparticle.
The combination of a protected blood transporting nanocarrier system and a tumor specific activation technology makes LiPlasome Pharma very competitive in a commercially attractive and dynamic anticancer market, where drug delivery systems will gain increasing importance over the coming years.
Living Cell is developing cell-based products to treat life threatening human diseases. The company has developed proprietary nanobiocapsules which allow encapsulated pig insulin producing cells, DiabeCell, to be implanted without the use of toxic immune suppressive drugs.
The company is focused on realizing the potential of RNAi-based therapeutics through the development of a broad-based, state-of-the-art drug discovery platform built upon industry leading expertise in RNA chemistry and oligonucleotide delivery.
MSI's technology for multi-step multi-analyte chemiluminescent assays combines microfluidics, nanotechnology, and optoelectronics designed for both Immunoassay and Nucleic Acid Hybridization based applications.
Meda Biotech is a clinical-stage biopharmaceutical company developing a new class of Hybrid- Nanoengineering™ platform enables the design, engineering and manufacturing of Hybrid water soluble drugs with unprecedented control over drug properties to maximize trafficking to disease sites, dramatically enhancing efficacy while minimizing toxicities.
MicroConstants is a GLP-compliant Contract Research Organization (CRO) dedicated to providing premier quality bioanalytical, drug metabolism, pharmacokinetic, formulation and immunoassay support services to pharmaceutical and biotech companies worldwide.
Micronit Microfluidics focuses on developing, prototyping and manufacturing lab-on-a-chip products. Micronit has extensive experience supplying microfluidic solutions to the life sciences industry. Capabilities include nanofluidic channels (depth down to 100 nm).
Mirexus Inc. is a natural biomaterials company that is commercializing a novel nanotechnology based on polysaccharide nanoparticles that can be used in a wide variety of markets ranging from cosmetics to nutraceuticals to biomedical applications in animal and human health. This technology was originally developed at the University of Guelph in the laboratories of Professor John Dutcher.